Promise and challenges in drug discovery and development of hybrid anticancer drugs

Expert Opinion on Drug Discovery

Volumn 4, Issue 11, 2009, Pages 1099-1111

  Gediya, Lalji K ^a   Njar, Vincent Co ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Anticancer drugs; Cancer; Drug discovery and development; Hybrid drugs

Indexed keywords

ACETYLSALICYLIC ACID DERIVATIVE; ANTINEOPLASTIC AGENT; AZASTEROID NITROGEN MUSTARD; AZATOXIN; CAMPTOTHECIN; COLCHICINE; CYTARABINE; ELIPTICINE; EPIPODOPHYLLOTOXIN; ESTRAMUSTINE; ETOPOSIDE; FLUOROURACIL; GLYCYRRHETINIC ACID; LACTANDRATE; LACTESTOXATE; NITRIC OXIDE ACETYLSALICYLIC ACID; PACLITAXEL DERIVATIVE; RETINOIC ACID; UNCLASSIFIED DRUG;

ADVANCED CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RESISTANCE; CHEMISTRY; DRUG ACTIVITY; DRUG DESIGN; DRUG MANUFACTURE; DRUG MECHANISM; DRUG RELEASE; DRUG RESEARCH; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; HYBRID; IN VIVO STUDY; PRIORITY JOURNAL; REVIEW;

EID: 72949087797     PISSN: 17460441     EISSN: None     Source Type: Journal    
DOI: 10.1517/17460440903341705     Document Type: Review

References (80)

1. Dunham W. Report sees 7.6 million global 2007 cancer deaths. American Cancer Society; 2007
2. Miller A, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-214
3. Brown SB, Brown EA, Walker I. The present and future role of photodynamic therapy in cancer treatment. Lancet Oncol 2004;5:497-508
4. Madhani M, Patra AK, Miller TW, et al. Biological activity of designed photolabile metal nitrosyls: light-dependent activation of soluble guanylate cyclase and vasorelaxant properties in rat aorta. J Med Chem 2006;49:7325-7330
5. van Lier JE, Tian H, Ali H, et al. Trisulfonated porphyrazines: new photosensitizers for the treatment of retinal and subretinal edema. J Med Chem 2009;52:889-905
6. Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med 2002;53:615-627
7. Marx JL. Drug resistance of cancer cells probed. Science 1986;234:818-820
8. Zimmermann GR, Lehár J, Keith CT. Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today 2007;12:34-42
9. Eymard JC, Priou F, Zannetti A, et al. Randomized phase II study of docetaxel plus estramustine and single-agent docetaxel in patients with metastatic hormone-refractory prostate cancer. Ann Oncol 2007;18:1064-1070
10. Fizazi K, Le Maitre A, Hudes G, et al. Meta-analysis of Estramustine in Prostate Cancer (MECaP) Trialists' Collaborative Group: addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data. Lancet Oncol 2007;8:994-1000
11. Machiels JP, Mazzeo F, Clausse M, et al. Prospective randomized study comparing docetaxel, estramustine, and prednisone with docetaxel and prednisone in metastatic hormone-refractory prostate cancer. J Clin Oncol 2008;26:5261-5268
12. Sporn MB. Dichotomies in cancer research: some suggestions for a new synthesis. Nat Clin Pract Oncol 2006;3:364-373
13. Sporn MB, Suh N. Chemoprevention: an essential approach to controlling cancer. Nat Rev Cancer 2002;2:537-543
14. Morphy R, Rankovic Z. Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem 2005;48:6523-6543
15. Frantz S. The trouble with making combination drugs. Nat Rev Drug Discov 2006;5:881-882
16. Morphy R, Kay C, Rankovic Z. From magic bullets to designed multiple ligands. Drug Discov Today 2004;9:641-651
17. Meunier B. Hybrid molecules with a dual mode of action: dream or reality? Acc Chem Res 2008;41:69-77
18. Tew KD, Stearns ME. Hormone-independent, non-alkylating mechanism of cytotoxicity for estramustine. Urol Res 1987;15:155-160
19. Trafalis DT. Hybrid aza-steroid alkylators in the treatment of colon cancer. Cancer Lett 2006;243:202-210
20. Cline SD, Macdonald TL, Osheroff N. Azatoxin is a mechanistic hybrid of the topoisomerase II-targeted anticancer drugs etoposide and ellipticine. Biochemistry 1997;36:13095-13101
21. Viegas-Junior C, Danuello A, da Silva Bolzani V, et al. Molecular hybridization: a useful tool in the design of new drug prototypes. Curr Med Chem 2007;14:1829-1852
22. Hulsman N, Medema JP, Bos C, et al. Chemical insights in the concept of hybrid drugs: the antitumor effect of nitric oxide-donating aspirin involves a quinone methide but not nitric oxide nor aspirin. J Med Chem 2007;50:2424-2431
23. Nudelman A, Rephaeli A. novel mutual prodrug of retinoic and butyric acids with enhanced anticancer activity. J Med Chem 2000;43:2962-2966
24. Daehne W, Frederiksen E, Gundersen E, et al. Acyloxymethyl esters of ampicillin. J Med Chem 1970;13:607-612
25. Alexander J, Cargill R, Michelson SR, Schwam H. (Acyloxy) alkyl carbamates as novel bioreversible prodrugs for amines: increased permeation through biological membranes. J Med Chem 1988;31:318-322
26. Greenwald RB, Pendri A, Conover CD, et al. Drug delivery systems employing 1, 4-or 1, 6-elimination: poly (ethylene glycol) prodrugs of amine-containing compounds. J Med Chem 1999;42:3657-3667
27. Barnes KR, Kutikov A, Lippard SJ. Synthesis, characterization, and cytotoxicity of a series of estrogen-tethered platinum(IV) complexes. Chem Biol 2004;11:557-564
28. Guzzo PR, Dinn SR, Lu J, Oettinger-Loomis S. Preparation of optically active (acyloxy) alkyl esters from optically active O-acyl-alpha-hydroxy acids. Tetrahedron Lett 2002;43:5685-5689
29. Kantoff P. Recent progress in management of advanced prostate cancer. Oncology (Williston) 2005;19:631-636
30. Hulsman N, Medema JP, Bos C, et al. Chemical insights in the concept of hybrid drugs: the antitumor effect of nitric oxide-donating aspirin involves a quinone methide but not nitric oxide nor aspirin. J Med Chem 2007;50:2424-2431
31. Altucci L, Gronemeyer H. The promise of retinoids to fight against cancer. Nat Rev Cancer 2001;1:181-193
32. Miller AA, Kurschel E, Osieka R, Schmidt CG. Clinical pharmacology of sodium butyrate in patients with acute leukemia. Eur J Cancer Clin Oncol 1987;23:1283-1287
33. Candido E, Reeves R, Davie JR. Sodium butyrate inhibits histone deacetylation in cultured cells. Cell 1978;14:105-113
34. Chen TA, Allfrey VG. Rapid and reversible changes in nucleosome structure accompany the activation, repression, and superinduction of murine fibroblast protooncogenes c-fos and c-myc. Proc Natl Acad Sci 1987;84:5252-5256
35. Thorne AW, Kmiciek D, Mitchelson K, et al. Patterns of histone acetylation. Eur J Biochem 1990;193:701-713
36. Ogryzko VV, Schiltz RL, Russanova V, et al. The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell 1996;87:953
37. Wolffe AP. Sinful repression. Nature 1997;387:16-17
38. Lin RJ, Nagy L, Inoue S, et al. Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature 1998;391:811-814
39. Grignani F, De Matteis S, Nervi C, et al. Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Nature 1998;391:815-818
40. He LZ, Guidez F, Tribioli C, et al. Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL. Nat Genet 1998;18:126-135
41. Warrell RP, He LZ, Richon V, et al. Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J Natl Cancer Inst 1998;90:1621-1625
42. Mann KK, Rephaeli A, Colosimo AL, et al. A retinoid/butyric acid prodrug overcomes retinoic acid resistance in leukemias by induction of apoptosis. Mol Cancer Res 2003;1:903-912
43. Altucci L, Leibowitz MD, Ogilvie KM, et al. RAR and RXR modulation in cancer and metabolic disease. Nat Rev Drug Discov 2007;6:793-810
44. Reynolds CP, Matthay KK, Villablanca JG, Maurer BJ. Retinoid therapy of high-risk neuroblastoma. Cancer Lett 2003;197:185-192
45. Freemantle SJ, Spinella MJ, Dmitrovsky E. Retinoids in cancer therapy and chemoprevention: promise meets resistance. Oncogene 2003;22:7305-7315
46. Sun SY, Wan H, Yue P, et al. Evidence that retinoic acid receptor beta induction by retinoids is important for tumor cell growth inhibition. J Biol Chem 2000;275:17149-17153
47. Sirchia SM, Ferguson AT, Sironi E, et al. Evidence of epigenetic changes affecting the chromatin state of the retinoic acid receptor beta2 promoter in breast cancer cells. Oncogene 2000;19:1556-1563
48. Widschwendter M, Berger J, Hermann M, et al. Methylation and silencing of the retinoic acid receptor-beta2 gene in breast cancer. J Natl Cancer Inst 2000;92:826-832
49. Gediya LK, Belosay A, Khandelwal A, et al. Improved synthesis of histone deacetylase inhibitors (HDIs) (MS-275 and CI-994) and inhibitory effects of HDIs alone or in combination with RAMBAs or retinoids on growth of human LNCaP prostate cancer cells and tumor xenografts. Bioorg Med Chem 2008;16:3352-3360
50. Gediya LK, Chopra P, Purushottamachar P, et al. A new simple and high-yield synthesis of suberoylanilide hydroxamic acid and its inhibitory effect alone or in combination with retinoids on proliferation of human prostate cancer cells. J Med Chem 2005;48:5047-5051
51. Hess-Stumpp H, Bracker TU, Henderson D, Politz O. MS-275, a potent orally available inhibitor of histone deacetylases-the development of an anticancer agent. Int J Biochem Cell Biol 2007;39:1388-1405
52. Verheul HMW, Qian DZ, Carducci MA, Pili R. Sequence-dependent antitumor effects of differentiation agents in combination with cell cycle-dependent cytotoxic drugs. Cancer Chemother Pharmacol 2007;60:329-339
53. Gediya LK, Khandelwal A, Patel J, et al. Design, synthesis, and evaluation of novel mutual prodrugs (hybrid drugs) of all-trans-retinoic acid and histone deacetylase inhibitors with enhanced anticancer activities in breast and prostate cancer cells in vitro. J Med Chem 2008;51:3895-3904
54. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003;3:330-338
55. Lennard L. Therapeutic drug monitoring of antimetabolic cytotoxic drugs. Br J Clin Pharmacol 1999;47:131
56. Menger FM, Rourk MJ. Synthesis and reactivity of 5-fluorouracil/ cytarabine mutual prodrugs. J Org Chem 1997;62:9083-9088
57. Shirao K, Hoff P, Ohtsu A, et al. Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV. J Clin Oncol 2004;22:3466
58. Engel D, Nudelman A, Tarasenko N, et al. Novel prodrugs of tegafur that display improved anticancer activity and antiangiogenic properties. J Med Chem 2008;51:314-323
59. Ohtsu H, Nakanishi Y, Bastow KF, et al. Antitumor agents 216. Synthesis and evaluation of paclitaxel-camptothecin conjugates as novel cytotoxic agents. Bioorg Med Chem 2003;11:1851-1857
60. Shi Q, Wang HK, Bastow KF, et al. Antitumor agents 210. Synthesis and evaluation of taxoid-epipodophyllotoxin conjugates as novel cytotoxic agents. Bioorg Med Chem 2001;9:2999-3004
61. Bastow KF, Wang HK, Cheng YC, Lee KH. Antitumor agents-CLXXIII. Synthesis and evaluation of camptothecin-4 beta-amino-4¢-O-demethyl epipodophyllotoxin conjugates as inhibitors of mammalian DNA topoisomerases and as cytotoxic agents. Bioorg Med Chem 1997;5:1481-1488
62. Nakagawa-Goto K, Nakamura S, Bastow KF, et al. Antitumor agents. 256. Conjugation of paclitaxel with other antitumor agents: evaluation of novel conjugates as cytotoxic agents. Bioorg Med. Chem Lett 2007;17:2894-2898 (Pubitemid 46656458)
63. Rink SM, Yarema KJ, Solomon MS, et al. Synthesis and biological activity of DNA damaging agents that form decoy binding sites for the estrogen receptor. Proc Natl Acad Sci USA 1996;93:15063-15068
64. Mitra K, Marquis JC, Hillier SM, et al. A rationally designed genotoxin that selectively destroys estrogen receptor-positive breast cancer cells. J Am Chem Soc 2002;124:1862-1863
65. Sharma U, Marquis JC, Nicole Dinaut A, et al. Design, synthesis, and evaluation of estradiol-linked genotoxicants as anti-cancer agents. Bioorg Med. Chem Lett 2004;14:3829-3833
66. Barnard C. Platinum anti-cancer agents. Platinum Metals Rev 1989;33:162-167
67. Hess SM, Anderson JG, Bierbach U. A non-crosslinking platinum-acridine hybrid agent shows enhanced cytotoxicity compared to clinical BCNU and cisplatin in glioblastoma cells. Bioorg Med. Chem Lett 2005;15:443-446
68. Kelland LR, Farrell N. Platinum-based drugs in cancer therapy. Humana Pr, Inc.; 2000
69. Provencher-Mandeville J, Descoteaux C, Mandal SK, et al. Synthesis of 17beta-estradiol-platinum(II) hybrid molecules showing cytotoxic activity on breast cancer cell lines. Bioorg Med. Chem Lett 2008;18:2282-2287
70. Marquis JC, Hillier SM, Dinaut AN, et al. Disruption of gene expression and induction of apoptosis in prostate cancer cells by a DNA-damaging agent tethered to an androgen receptor ligand. Chem Biol 2005;12:779-787
71. Lipinski CA. Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods 2000;44:235-249
72. Veber DF, Johnson SR, Cheng HY, et al. Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem 2005;45(12):2615-2623
73. Bradshaw TD, Westwell AD. The development of the antitumour benzothiazole prodrug, Phortress, as a clinical candidate. Curr Med. Chem 2004;11:1009-1021
74. Sinko PJ, Balimane PV. Carrier-mediated intestinal absorption of valacyclovir, the L-valyl ester prodrug of acyclovir: 1. Interactions with peptides, organic anions and organic cations in rats. Biopharm Drug Dispos 1998;19(4):209-217
75. Lorenzi PL, Landowski CP, Song X, et al. Amino acid ester prodrugs of 2-bromo-5,6-dichloro-1-(beta-Dribofuranosyl) benzimidazole enhance metabolic stability in vitro and in vivo. J Pharmacol Exp Ther 2005;314:883-890
76. Berenbaum MC. What is synergy? Pharmacol Rev 1989;41:93-141
77. Greco WR, Bravo G, Parsons JC. The search for synergy: a critical review from a response surface perspective. Pharmacol Rev 1995;47:331-385
78. Zhao L, Wientjes MG, Au JL. Evaluation of combination chemotherapy: integration of nonlinear regression, curve shift, isobologram, and combination index analyses. Clin Cancer Res 2004;10:7994-8004
79. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006;58:621
80. Gunnarsson P, Andersson SB, Johansson SÅ, et al. Pharmacokinetics of estramustine phosphate (Estracyt®) in prostatic cancer patients. Eur J Clin Pharmacol 1984;26(1):113-119